A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy
Phase of Trial: Phase I
Latest Information Update: 03 May 2018
At a glance
- Drugs WVE 210201 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man
- Sponsors WaVe life Sciences
- 03 May 2018 New source identified and integrated (European Clinical Trials Database; EudraCT2017-002686-21).
- 12 Mar 2018 According to a WaVe life Sciences media release, Safety data from the trial are anticipated in Q3 2018 and expected to facilitate the rapid transition to an open-label extension study and efficacy study.
- 09 Nov 2017 According to a WaVe life Sciences media release, this study including an open-label extension study are designed to include an interim efficacy readout of dystrophin expression from muscle biopsies in 2H 2019.